Bristol Myers Squibb is a drug manufacturers - general business based in the US. Bristol Myers Squibb shares (BMY) are listed on the NYSE and all prices are listed in US Dollars.
Its last market close was $56.85 – a decrease of 3.56% over the previous week. Bristol Myers Squibb employs 34,100 staff and has a trailing 12-month revenue of around $47.4 billion.Our top picks for where to buy Bristol-Myers Squibb Company stock
How to buy Bristol Myers Squibb stock
- Choose a stock trading platform. Compare investment platforms.
- Open an account. Provide your personal information and sign up.
- Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
- Search for the stock name – BMY. Search for the stock by name or ticker symbol.
- Buy the stock. Place your order. It's that simple.
Buy Bristol-Myers Squibb Company stock from these online trading platforms
Compare special offers, low fees and a wide range of investment options among top trading platforms.Note: The dollar amounts in the table below are in Canadian dollars.
Finder Score for stock trading platforms
To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.
Bristol Myers Squibb stock price (NYSE: BMY)
Use our graph to track the performance of BMY stocks over time.Bristol Myers Squibb stocks at a glance
Latest market close | $56.85 |
---|---|
52-week range | $38.18 - $61.10 |
50-day moving average | $57.78 |
200-day moving average | $50.10 |
Wall St. target price | $61.72 |
PE ratio | N/A |
Dividend yield | $2.4 (4.15%) |
Earnings per share (TTM) | $-3.58 |
Is it a good time to buy Bristol Myers Squibb stock?
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Bristol Myers Squibb price performance over time
Historical closes compared with the close of $57.42 from 2025-02-06
1 week (2025-01-31) | -2.60% |
---|---|
1 month (2025-01-07) | 0.49% |
3 months (2024-11-08) | 6.06% |
6 months (2024-08-07) | 23.48% |
1 year (2024-02-08) | 17.88% |
---|---|
2 years (2023-02-08) | -14.91% |
3 years (2022-02-08) | 58.6039 |
5 years (2020-02-07) | 3.81% |
Is Bristol Myers Squibb stock undervalued or overvalued?
Valuing Bristol Myers Squibb stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Bristol Myers Squibb's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Bristol Myers Squibb's PEG ratio
Bristol Myers Squibb's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 2.0894. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Bristol Myers Squibb's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.
Bristol Myers Squibb's EBITDA
Bristol Myers Squibb's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $19.2 billion.
The EBITDA is a measure of a Bristol Myers Squibb's overall financial performance and is widely used to measure a its profitability.
Bristol Myers Squibb financials
Revenue TTM | $47.4 billion |
---|---|
Operating margin TTM | 18.48% |
Gross profit TTM | $36 billion |
Return on assets TTM | 6.07% |
Return on equity TTM | -31.33% |
Profit margin | -15.3% |
Book value | $8.45 |
Market Capitalization | $116.5 billion |
TTM: trailing 12 months
Bristol Myers Squibb's environmental, social and governance track record
Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Bristol Myers Squibb.
When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.
Bristol Myers Squibb's total ESG risk score
Total ESG risk: 29.16
Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Bristol Myers Squibb's overall score of 29.16 (as at 12/31/2018) is nothing to write home about – landing it in it in the 53rd percentile of companies rated in the same sector.
ESG scores are increasingly used to estimate the level of risk a company like Bristol Myers Squibb is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).
Bristol Myers Squibb's environmental score
Environmental score: 3.83/100
Bristol Myers Squibb's environmental score of 3.83 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol Myers Squibb is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.
Bristol Myers Squibb's social score
Social score: 18.82/100
Bristol Myers Squibb's social score of 18.82 puts it squarely in the 4th percentile of companies rated in the same sector. This could suggest that Bristol Myers Squibb is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.
Bristol Myers Squibb's governance score
Governance score: 14.02/100
Bristol Myers Squibb's governance score puts it squarely in the 4th percentile of companies rated in the same sector. That could suggest that Bristol Myers Squibb is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.
Bristol Myers Squibb's controversy score
Controversy score: 2/5
ESG scores also evaluate any incidences of controversy that a company has been involved in. Bristol Myers Squibb scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Bristol Myers Squibb has, for the most part, managed to keep its nose clean.
Environmental, social, and governance (ESG) summary
Bristol-Myers Squibb Company was last rated for ESG on: 2019-01-01.
Total ESG score | 29.16 |
---|---|
Total ESG percentile | 52.58 |
Environmental score | 3.83 |
Environmental score percentile | 4 |
Social score | 18.82 |
Social score percentile | 4 |
Governance score | 14.02 |
Governance score percentile | 4 |
Level of controversy | 2 |
Bristol Myers Squibb stock dividends
Dividend payout ratio: 2.12% of net profits
Recently Bristol Myers Squibb has paid out, on average, around 0% of net profits as dividends. That has enabled analysts to estimate a "forward annual dividend yield" of 0% of the current stock value. This means that over a year, based on recent payouts (which are sadly no guarantee of future payouts), Bristol Myers Squibb shareholders could enjoy a 0% return on their shares, in the form of dividend payments. In Bristol Myers Squibb's case, that would currently equate to about $2.4 per share.
While Bristol Myers Squibb's payout ratio might seem low, this can signify that Bristol Myers Squibb is investing more in its future growth.
Bristol Myers Squibb's most recent dividend payout was on 2 February 2025. The latest dividend was paid out to all shareholders who bought their stocks by 2 January 2025 (the "ex-dividend date").
Have Bristol Myers Squibb's stocks ever split?
Bristol Myers Squibb's stocks were split on a 1000000:95 basis on 6 August 2001 . So if you had owned 95 shares the day before before the split, the next day you'd have owned 1000000 shares. This wouldn't directly have changed the overall worth of your Bristol Myers Squibb stocks – just the quantity. However, indirectly, the new 100% lower stock price could have impacted the market appetite for Bristol Myers Squibb stocks, which in turn could have impacted Bristol Myers Squibb's stock price.
Bristol Myers Squibb stock price volatility
Over the last 12 months, Bristol Myers Squibb's stocks have ranged in value from as little as $38.1829 up to $61.1. A popular way to gauge a stock's volatility is its "beta."
Beta is a measure of a stocks volatility in relation to the market. The market (NYSE average) beta is 1, while Bristol Myers Squibb's is 0.441. This would suggest that Bristol Myers Squibb's stocks are less volatile than average (for this exchange).
Bristol Myers Squibb overview
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia. It also provides Yervoy for the treatment of patients with unresectable or metastatic melanoma; Empliciti for the treatment of multiple myeloma; Abecma for the treatment of relapsed or refractory multiple myeloma; Reblozyl for the treatment of anemia; Opdualag for the treatment of unresectable or metastatic melanoma; and Zeposia to treat relapsing forms of multiple sclerosis. In addition, the company offers Breyanzi for the treatment of relapsed or refractory large B-cell lymphoma; Onureg for the treatment of AML; Inrebic for the treatment of myelofibrosis; Camzyos for the treatment of symptomatic obstructive HCM to enhance functional capacity and symptom; Sotyktu for the treatment of moderate-to-severe plaque psoriasis; Augtyro for the treatment of locally advanced or metastatic ROS1-positive NSCLC; Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; and Abraxane to treat breast cancer, NSCLC and pancreatic cancer. It sells products to wholesalers, distributors, pharmacies, retailers, hospitals, clinics, and government agencies. The company was formerly known as Bristol-Myers Company.
Frequently asked questions
What percentage of Bristol Myers Squibb is owned by insiders or institutions?Currently 0.115% of Bristol Myers Squibb stocks are held by insiders and 78.524% by institutions. How many people work for Bristol Myers Squibb?
Latest data suggests 34,100 work at Bristol Myers Squibb. When does the fiscal year end for Bristol Myers Squibb?
Bristol Myers Squibb's fiscal year ends in December. Where is Bristol Myers Squibb based?
Bristol Myers Squibb's address is: Route 206 & Province Line Road, Princeton, NJ, United States, 08543 What is Bristol Myers Squibb's ISIN number?
Bristol Myers Squibb's international securities identification number is: US1101221083 What is Bristol Myers Squibb's CUSIP number?
Bristol Myers Squibb's Committee on Uniform Securities Identification Procedures number is: 110122108
More on investing

How do ETFs work?
Your guide to how ETFs work and whether this type of investment is right for you.
Read more…
How to read stock charts
Learning how to read stock charts and recognize chart patterns can unlock your success as a trader.
Read more…
What are stocks?
Owning a stock means you own part of a company and can potentially grow your wealth. But there is a risk of loss.
Read more…More guides on Finder
-
Best renewable energy stocks
These are the best renewable energy stocks to buy now in Canada.
-
Best stocks to buy right now in Canada
Finder’s unique algorithm found the 20 best TSX stocks to buy right now.
-
5 Best ETFs in Canada for 2025
Looing for the best performing ETF in Canada? Explore the best Canadian ETFs on the TSX for dividend, REIT, bond investing and more.
-
4 Best US ETFs for 2025
Looing for the best US ETF? Explore the best US ETFs, including top US dividend and Nasdaq funds.
-
10 best stock trading platforms and apps in Canada for 2025
Whether you’re a new or experienced investor, these are the best stock trading platforms and apps in Canada.
-
How to buy US stocks in Canada
Buying US stocks in Canada is easier than you think. Find out how to buy US stocks in 4 simple steps.
-
How to invest in the S&P 500 in Canada
Find out how to invest in the S&P 500 in Canada—one of the world’s most popular stock indices—to diversify your portfolio.
-
BMO InvestorLine review
Check out the pros and cons of BMO’s self-directed trading platform in our InvestorLine review.
-
How to trade options in Canada
What is options trading and are options better than stocks? Learn how options trading in Canada works.
-
How to buy stocks in Canada
Want to know how to buy and sell stocks in Canada? Find out what you need to know in this simple, step-by-step guide.